ConvaTec shares drop nearly 5% despite strong start and maintained 2026 revenue guidance

ConvaTec Group PLC shares fell almost 5% despite the company reporting a good start to 2026 and maintaining its full-year organic revenue growth guidance of 5.0-7.0%. The company saw 4.8% organic revenue growth in the first four months, excluding its InnovaMatrix product, with all divisions performing as expected. Growth in the Infusion Care segment was slightly slower due to tough comparisons and order timing, but the company signed its first insulin patch pump supply agreement in this fast-growing market. Analysts view the maintained guidance and positive start as reassuring, suggesting a potential relief rally after recent share price weakness.